KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

4 Customer Reviews


    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.


    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.



    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK4TWM2OD1|LkK3N|UzKM7:TR?= MWjTRW5ITVJ?
HuO-3N1 M1jUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwMUexOFIh|ryP MVLTRW5ITVJ?
LAMA-84 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDiTWM2OD12LkW4OFY2KM7:TR?= NHTMb5VUSU6JRWK=
LoVo M2Dnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXESGFlUUN3ME22Mlk{OjN7IN88US=> MYTTRW5ITVJ?
SK-MEL-3 NUfOT5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzyTWM2OD16LkK4OVc2KM7:TR?= NYDpV4ZqW0GQR1XS
KM12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPQdYpKSzVyPUmuNlEyPDJizszN MYrTRW5ITVJ?
NCI-H1437 NELifoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTJbVRKSzVyPUmuPFA6PyEQvF2= MYfTRW5ITVJ?
NCI-H1838 NVrkR2lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnF[FJKSzVyPUGxMlE5PjVizszN NELqeo5USU6JRWK=
J-RT3-T3-5 M3S3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X0bmlEPTB;MUGuNlQyPyEQvF2= MUjTRW5ITVJ?
GOTO NG[0ZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrjWWtzUUN3ME2xNU43QTl4IN88US=> M2jxZ3NCVkeHUh?=
LB2241-RCC M{nuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIToW3pKSzVyPUGxMlcyQDZizszN MYHTRW5ITVJ?
ES7 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFzLke4PEDPxE1? NFXvZYpUSU6JRWK=
CAL-12T M1XOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF|Lk[xO{DPxE1? M3S0fnNCVkeHUh?=
COLO-684 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF2LkG1Olkh|ryP NX7NN3Y6W0GQR1XS
DOK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF3LkOzNlkh|ryP MYnTRW5ITVJ?
Hs-578-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjyXo1KSzVyPUG1MlQyQDJizszN MWHTRW5ITVJ?
D-423MG NFqzNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz1eJhlUUN3ME2xOU42OjN4IN88US=> NHjaZpZUSU6JRWK=
DBTRG-05MG MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF3Lk[xNVEh|ryP M{\QXXNCVkeHUh?=
VM-CUB-1 NEfXe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnKXWlKSzVyPUG1Mlk5PDlizszN NYTyRVJSW0GQR1XS
KG-1 MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX0cXdKSzVyPUG2MlA6QTZizszN M3XxNHNCVkeHUh?=
8305C MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jCPWlEPTB;MU[uNVg5QSEQvF2= MlfHV2FPT0WU
HuH-7 M2LxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe1[XhKSzVyPUG2MlI3PzRizszN NYXhfnU6W0GQR1XS
LXF-289 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCyOG5QUUN3ME2xOk4zPzR5IN88US=> Ml3BV2FPT0WU
NCI-H1793 NHn3VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF4LkS3NVIh|ryP M1q2PXNCVkeHUh?=
ChaGo-K-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPrW4MzUUN3ME2xOk43PTZ6IN88US=> M2nhR3NCVkeHUh?=
SK-MEL-28 M3mzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjsVpZKSzVyPUG3MlA1PzVizszN M3fqcXNCVkeHUh?=
NCI-SNU-1 NFXtc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PlcmlEPTB;MUeuNVI3QSEQvF2= NYXmVVMzW0GQR1XS
NCI-H82 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF5LkS1O|Mh|ryP MXPTRW5ITVJ?
HCC2998 M1zjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HTUGlEPTB;MUeuOlc{OyEQvF2= MVLTRW5ITVJ?
NCI-H2030 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfOTWM2OD1zOD6xPVk4KM7:TR?= NWTv[4U{W0GQR1XS
HuP-T3 M3z5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom4TWM2OD1zOD61PFg5KM7:TR?= NETXSlBUSU6JRWK=
697 M4[wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF7LkCyNFEh|ryP NGDKfHNUSU6JRWK=
MLMA M{jSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml62TWM2OD1zOT6wOVU4KM7:TR?= NEnvSnhUSU6JRWK=
HCC70 M3XqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLvclhKSzVyPUG5MlQ5QSEQvF2= MXvTRW5ITVJ?
A704 M1rGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW0TWM2OD1zOT64N|A2KM7:TR?= M1LvR3NCVkeHUh?=
D-283MED NX;NXJJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJyLkWzN|kh|ryP NH62b4ZUSU6JRWK=
U031 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\KTWM2OD1{MT6xOFg6KM7:TR?= NXjDdo1zW0GQR1XS
HSC-3 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfBU4R2UUN3ME2yNU4yQDN3IN88US=> Mlf5V2FPT0WU
Mewo NG\EelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ{LkWwO|Mh|ryP Mkj6V2FPT0WU
YH-13 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzzRYdKSzVyPUKyMlUyOjNizszN MUnTRW5ITVJ?
LB1047-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\pcXFHUUN3ME2yNk42QDd7IN88US=> MlvVV2FPT0WU
HCC2157 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\1TWM2OD1{Mj64NFU1KM7:TR?= MmHNV2FPT0WU
SNU-449 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTWTWM2OD1{Mj64O|Q5KM7:TR?= NVLzRWk1W0GQR1XS
Ramos-2G6-4C10 NXLzdpVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[2fIxKUUN3ME2yNk46PiEQvF2= NGLKZpJUSU6JRWK=
CHL-1 NX\CbGloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\KTmlEPTB;MkOuO|I6OiEQvF2= NIDIe2hUSU6JRWK=
SK-MEL-30 M1PtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zRTmlEPTB;MkSuOFY3OiEQvF2= MVXTRW5ITVJ?
PANC-08-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknyTWM2OD1{NT6wPVM5KM7:TR?= MnzxV2FPT0WU
BFTC-905 NUf4UI9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rYOGlEPTB;MkWuOVk1PCEQvF2= MmrzV2FPT0WU
GI-1 M1\RXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInNXpVKSzVyPUK1MlcxPTVizszN MXvTRW5ITVJ?
MDA-MB-415 NFnGNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LWUmlEPTB;Mk[uOVA{OyEQvF2= M3rDPHNCVkeHUh?=
DEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor2TWM2OD1{Nj64N|U3KM7:TR?= MVjTRW5ITVJ?
RVH-421 M4X6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm5SJBKSzVyPUK3MlI6OjFizszN NU\ZSFBwW0GQR1XS
EW-13 NGrh[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ5LkSzNFgh|ryP NITHcnlUSU6JRWK=
639-V NYLUfY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqyTWM2OD1{Nz61NVE6KM7:TR?= MWrTRW5ITVJ?
A2780 M{ezcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml24TWM2OD1{Nz62OFEh|ryP M1HUbnNCVkeHUh?=
SW982 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELqWnNKSzVyPUK3MlkxPTJizszN M1zzZnNCVkeHUh?=
SW1710 M{XSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjybFhKSzVyPUK4MlA6QDFizszN MV\TRW5ITVJ?
HCC1569 NVTDSVd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrPXmxrUUN3ME2yPE41QDl5IN88US=> M1\EV3NCVkeHUh?=
MV-4-11 NWDXR21zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ6LkW3N|Uh|ryP NEPGdpZUSU6JRWK=
BHT-101 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnBR41KSzVyPUK4MlY2PzJizszN NFjJRVhUSU6JRWK=
Ca9-22 NELmeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nDWmlEPTB;MkiuO|E1KM7:TR?= Mn\PV2FPT0WU
HAL-01 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ6Lke2NVUh|ryP M2KyT3NCVkeHUh?=
D-263MG NYe4TXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTacXpqUUN3ME2yPU4{PDRizszN MnPJV2FPT0WU
NEC8 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW0TWM2OD1{OT61OVQ5KM7:TR?= NXfDe2x7W0GQR1XS
EKVX NYmw[XA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNzLkW4OFch|ryP M2PZcnNCVkeHUh?=
EM-2 NH\vfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTxb2pKSzVyPUOxMlY{ODRizszN NH\jXHNUSU6JRWK=
MFM-223 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[5OmNKSzVyPUOxMlgxQThizszN MV\TRW5ITVJ?
SK-PN-DW M1HXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTN{LkG0NFYh|ryP NI\hdZlUSU6JRWK=
HuO9 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2yTWM2OD1|Mj61NlgzKM7:TR?= NHj1eldUSU6JRWK=
OVCAR-4 NEnpcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPWTWM2OD1|Mj64N|Y{KM7:TR?= NEOwdmxUSU6JRWK=
NCI-H1648 M{jMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLxZXlGUUN3ME2zNk45PjVzIN88US=> NFTvPY9USU6JRWK=
MS-1 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTN2Lkm1OVQh|ryP MmHzV2FPT0WU
HOP-92 NEnmWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnXco06UUN3ME2zOU46Ojd5IN88US=> NWq5V21IW0GQR1XS
TE-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTsVI5KSzVyPUO2MlUzPDNizszN NVT5Unh4W0GQR1XS
SK-NEP-1 M4TCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN5Lk[3OFQh|ryP NF:3PFlUSU6JRWK=
COLO-829 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W5NmlEPTB;M{iuOFE2QSEQvF2= M4ixTXNCVkeHUh?=
NCI-H2228 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRyLkO2OlIh|ryP NYXmemd1W0GQR1XS
C32 M17JOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknJTWM2OD12MD60NFI1KM7:TR?= M3H6d3NCVkeHUh?=
KU-19-19 M4X5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrVW4RKSzVyPUSwMlc3QDNizszN NXnLe3lQW0GQR1XS
KNS-62 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRyLkizPFEh|ryP MUfTRW5ITVJ?
FADU M3\uZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHk[WNKSzVyPUSxMlI2ODJizszN MV\TRW5ITVJ?
CAL-33 NV;6T21uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq2TWM2OD12Mj62O|Q6KM7:TR?= NILJTGtUSU6JRWK=
HDLM-2 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG1bHhEUUN3ME20Nk46ODh2IN88US=> NGf6T5ZUSU6JRWK=
NBsusSR MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3ESJhKSzVyPUSzMlA4OjVizszN MkO1V2FPT0WU
A549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq0b486UUN3ME20N{46OzFizszN NEn3b5VUSU6JRWK=
NKM-1 NFn0bYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;tepBKSzVyPUSzMlk2PThizszN M{\r[3NCVkeHUh?=
DMS-273 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPPOndKSzVyPUS0Mlc2PjdizszN MWPTRW5ITVJ?
TYK-nu MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKxPY1KUUN3ME20OU4yOjN2IN88US=> Mk[zV2FPT0WU
KALS-1 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\HTWM2OD12NT6xOFYh|ryP MnPIV2FPT0WU
A101D M1Hwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqzSpVTUUN3ME20OU41PDV4IN88US=> NGiy[lRUSU6JRWK=
G-361 NGLCTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzDTWM2OD12Nj6yNVM5KM7:TR?= M{HpU3NCVkeHUh?=
KARPAS-299 M1;zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjuTWM2OD12Nj6zOVE3KM7:TR?= NEjrWppUSU6JRWK=
RS4-11 NXe5Z2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR4LkW0NkDPxE1? NHPnWotUSU6JRWK=
HT-1376 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTvOoV1UUN3ME20Ok44PDJ4IN88US=> MVjTRW5ITVJ?
SK-N-AS NGLvOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnntTWM2OD12Nj63PFIzKM7:TR?= NUOySXJ2W0GQR1XS
MG-63 NGm2[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r1[2lEPTB;NE[uPVA{PiEQvF2= NH3IOFNUSU6JRWK=
EPLC-272H Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzOTWM2OD12Nj65OVA{KM7:TR?= MYDTRW5ITVJ?
BALL-1 M1zicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH0dId3UUN3ME20O{45OzJizszN NEPMSY5USU6JRWK=
HO-1-N-1 M4rKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFXmhWUUN3ME20PE46Pjd4IN88US=> MmrZV2FPT0WU
MFE-280 M2n0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\SN5AxUUN3ME20PU41PjF5IN88US=> MWHTRW5ITVJ?
NCI-H526 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzmWI9KSzVyPUS5MlgyPjNizszN NVS4SpZsW0GQR1XS
D-566MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TGfGlEPTB;NEmuPVA6PiEQvF2= M17FVXNCVkeHUh?=
BB30-HNC Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTR7Lkm0PVgh|ryP NGjHcXZUSU6JRWK=
HepG2  M2joZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxNOKh|ryP MUmyOEBp Mo\LZoxw[2u|IGPDMWlKUTNvaX7keYNm\CCVIIDoZZNmKGG{cnXzeC=> M4fa[VI2PTJ5MUKz
HepG2  Mlz2SpVv[3Srb36gRZN{[Xl? M3LDZVExyqEQvF2= NYPIfphkOjRiaB?= Ml;kd5VxeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9veyCxZjDBWG0hd25iU3XyNVk5OSxiQ3jrNUBwdiCVZYKzOFUtKEOqa{Kgc44hXGi{NkisJIFv\CCFZHuyJI9vKFS7ckG1JIlv\HWlZXSgZpkhW0NvSVnJNy=> MYOyOVUzPzF{Mx?=
KATO III  M2C0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWyMlUwPS95LkWg{txO NXzTN41wTE2VTx?= Mkjv[Y5p[W6lZYOgeIhmKHSxeHnjbZR6KG:oIH;sZZBiemmk MorPNlQ5PDF5MUi=
hTCEpi NIHZN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rVdlExKM7:TR?= NE\EepBFVVOR NWLCNnA3eHKndnXueJMhfGinIHP5eI9x[XSqaXOg[YZn\WO2IH;mJGhUXi1z MUOyOFM4ODh|NR?=
MCF10A MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;yNVAh|ryP NID2PVQzPCCq NIO2SXJFVVOR NIm2R2xxd3SnboTpZZRmeyC2aHWgZ5l1d3SxeHnjbZR6KG:oIFfB MlqxNlQyPTB3OUW=
HL-60  Mly2SpVv[3Srb36gRZN{[Xl? Mm\LNVAh|ryP NHHzZ2kxNjViaB?= M2qwOmROW09? NV:3fZI4emWmdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMtMg NWLNWZhHOjN7M{S0NVE>
MCF-7 NWDj[IRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPX[Y4yNTFyMN88US=> MXyyOEBp NXv0XGhlTkKV NFPpS4pqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w MmXnNlMyQDV|NEe=
HeLa  NF7iS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzQNU0yODEQvF2= MlfiNlQhcA>? NWPyWG5mTkKV NYDpVm9pcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= NVPOUG1vOjNzOEWzOFc>
SH-SY5Y M2\R[WZ2dmO2aX;uJGF{e2G7 NH73SpgyOMLizszNxsA> NIDIZVEzPCCq NE\Dc3FqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= MYSyNlYzPzJ7NB?=
IMR-32 NUjsW4c4TnWwY4Tpc44hSXO|YYm= MYCxNOKh|ryPwrC= NEi4c4kzPCCq M{K3PIlvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| M2jvVVIzPjJ5Mkm0
A549 M2jsV2Z2dmO2aX;uJGF{e2G7 NHHhNGgyOMLizszNxsA> MmLMNUBp M1Hk[pN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36= NHK4SW8zOjV3OUOyNS=>
T47D  MWnGeY5kfGmxbjDBd5NigQ>? NULWcHZYOjEEoH3N NFHq[XYzPCCq NVHHOos6TE2VTx?= NVjzOJpmeHKndnXueJMhUVJvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= MlTINlEyPDR6MEW=
A29 MEF NXLxVWZ3TnWwY4Tpc44hSXO|YYm= MWexNOKh|ryPwrC= MoTCNYg> M1jWeYJtd2Otc9MgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgZZQhW2W{NEezxsA> M3Oz[|IxODV|N{ix
MDA-MB-453  Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG1MVQxKM7:TR?= MVK3NkBp MWXJR|UxKG:oIEGwJO69VQ>? NGjxdFAzODB3M{e4NS=>
PC-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:1MVQxKM7:TR?= M3vjZlczKGh? M3PYVGlEPTBib3[gNVAh|ryP MWiyNFA2Ozd6MR?=

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]


Kinase Assay:


+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:


+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO and 47.5% PEG300
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49


CAS No. 587871-26-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID